N/A N=55 Randomized Triple-blind Treatment

CompaRison of Paresthesia Mapping to anatomIc Midline-based burSt Programming Strategies

Chronic Pain

Bottom Line

View on ClinicalTrials.gov: NCT02986074 ↗

Enrolled (actual)

Serious AEs

10.9%

Results posted

May 2021

Primary outcome: Primary: Visual Analog Scale (VAS) for Back Pain at SCS Trial — 32; 30.5 units on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Paresthesia mapping lead evaluation first (Device); Anatomical midline lead evaluation first (Device)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Abbott Medical Devices
Primary completion: Aug 2019

Outcome Measures

Outcome	Result	p-value
PRIMARY Visual Analog Scale (VAS) for Back Pain at SCS Trial	32; 30.5	—
SECONDARY Visual Analog Scale (VAS) for Back Pain at 3 Months	28.5; 24.6	—
SECONDARY Visual Analog Scale (VAS) for Back Pain at 6 Months	24; 35.2	—
SECONDARY Visual Analog Scale (VAS) for Back Pain at 12 Months	24; 31.8	—
SECONDARY EQ-5D at SCS Trial	0.68; 0.65	—
SECONDARY EQ-5D at 3 Month	0.73; 0.63	—
SECONDARY EQ-5D at 6 Month	0.62; 0.64	—
SECONDARY EQ-5D at 12 Month	0.69; 0.67	—
SECONDARY ODI at SCS Trial	40.2; 41.8	—
SECONDARY ODI at 3 Months	33.8; 37.3	—
SECONDARY ODI at 6 Months	41.5; 36.9	—
SECONDARY ODI at 12 Months	33.9; 39.4	—
SECONDARY Satisfaction Questionnaire	0; 0; 1; 1; 0; 2	—
SECONDARY Satisfaction Questionnaire	0; 0; 1; 1; 0; 2	—
SECONDARY Satisfaction Questionnaire	0; 0; 1; 1; 0; 2	—

Summary

The study will compare therapeutic efficacy of a novel spinal cord stimulation leads implant based on anatomical landmarks with standard surgical implantation technique.

Eligibility Criteria

Inclusion Criteria

Subject is able to provide informed consent to participate in the study;
Subject is 18 years of age or older;
Subject has failed to respond to at least 6 months of conventional treatment including pharmacological treatment, physical therapy, epidural injections and/or radiofrequency therapy as per NICE Tag 0159;
FBSS subjects with predominant low back pain;
Subject has a lower back pain intensity of at least 6.0 out of 10.0 on the VAS at baseline;
Subject is on stable pain medications with a total opioid equivalent of 120 mgs a day or less for at least 28 days prior to enrolling in this study, and is willing to stay on those medications with no dose adjustments until activation of the permanently implanted SCS device;
Subject's medical record has been evaluated by the Investigator to ensure that the subject is a good candidate for a neurostimulation system;
Subject is willing to cooperate with the study requirements including compliance with the regimen and completion of all office visits;
Female candidates of child-bearing potential agree to commit to the use of an effective method of contraception (including but not limited to sterilization, barrier devices, oral contraceptives, intrauterine devices (IUDs), condoms, rhythm method, or abstinence) for the duration of the study

Exclusion Criteria

Subjects with significant scoliosis even if surgically corrected
Subject is currently participating in a clinical investigation that includes an active treatment arm;
Subject has been implanted with or participated in a trial period for a neurostimulation system;
Subject has an infusion pump;
Subject has evidence of an active disruptive psychological or psychiatric disorder as determined as per standard of care;
Subject has a current diagnosis of a coagulation disorder, bleeding diathesis, progressive peripheral vascular disease or uncontrolled diabetes mellitus;
Subject has a current diagnosis of a progressive neurological disease as determined by the Investigator;
Subject is immunocompromised;
Subject has an existing medical condition that is likely to require repetitive MRI evaluation in the future (i.e. epilepsy, stroke, multiple sclerosis, acoustic neuroma, tumor);
Subject has history of cancer requiring active treatment in the last 12 months;
Subject has an existing medical condition that is likely to require the use of diathermy in the future;
Subject has documented history of allergic response to titanium or silicone;
Subject has a documented history of substance abuse (narcotics, alcohol, etc.) or substance dependency in the 6 months prior to baseline data collection;
Female candidates of child bearing potential that are pregnant (confirmed by positive urine/blood pregnancy test).

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02986074). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.